Integrated Investment Consultants LLC bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,499 shares of the biopharmaceutical company’s stock, valued at approximately $279,000.
Other hedge funds also recently modified their holdings of the company. Garrett Wealth Advisory Group LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter valued at approximately $26,000. Lenox Wealth Advisors LLC grew its holdings in Bristol-Myers Squibb by 555.7% during the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its holdings in Bristol-Myers Squibb by 101.2% during the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 327 shares in the last quarter. Endurance Wealth Management Inc. grew its holdings in Bristol-Myers Squibb by 119.6% during the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 500 shares in the last quarter. Finally, HMS Capital Management LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $45,000. Institutional investors and hedge funds own 80.25% of the company’s stock.
Shares of Bristol-Myers Squibb stock traded up $2.18 during trading hours on Tuesday, hitting $55.38. The company had a trading volume of 14,395,677 shares, compared to its average volume of 9,842,616. The company’s 50-day moving average is $50.25 and its two-hundred day moving average is $47.28. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $54.81. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The company has a market cap of $86.74 billion, a P/E ratio of 13.91, a price-to-earnings-growth ratio of 1.25 and a beta of 0.72.
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a $0.41 dividend. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 2.96%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
Several research analysts have commented on the stock. ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Saturday. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target for the company in a report on Wednesday, August 14th. Bank of America initiated coverage on shares of Bristol-Myers Squibb in a report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 target price for the company. TheStreet upgraded shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, September 13th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $56.53.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, July 31st. The stock was purchased at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the transaction, the director now directly owns 11,397 shares in the company, valued at $509,673.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Further Reading: How to execute a trade ex-dividend strategy?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.